Holen Sie sich die Stockscreener-App
3.28
2.09%
-0.07
Handel nachbörslich:
3.28
Schlusskurs vom Vortag:
$3.35
Offen:
$3.35
24-Stunden-Volumen:
552.92K
Relative Volume:
0.88
Marktkapitalisierung:
$193.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-57.44M
KGV:
-2.4549
EPS:
-1.3361
Netto-Cashflow:
$-56.46M
1W Leistung:
-7.61%
1M Leistung:
-17.38%
6M Leistung:
-38.23%
1J Leistung:
-23.54%
1-Tages-Spanne:
$3.23
$3.44
1-Wochen-Bereich:
$3.23
$3.88
52-Wochen-Spanne:
$3.23
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Firmenname
Protara Therapeutics Inc
Sektor
Branche
Telefon
646-844-0337
Adresse
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
3.28 | 193.83M | 0 | -57.44M | -56.46M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-04 | Eingeleitet | JP Morgan | Overweight |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-10 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-17 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-07-29 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten
TARA: TARA-002 demonstrates robust efficacy and safety in pivotal trials for NMIBC and LMs, with key milestones ahead - TradingView
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
A company developing cancer and rare-disease treatments will present at a conference Sept. 15. - Stock Titan
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Protara (TARA) Results Check: The Bottom-Line Figure Outpaces Its Comparison at the Close; Post-Earnings: The Share Price Sheds 1.28% in the Available RecordEarnings Volatility Report - careplusvn.com
Protara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should Watch - TipRanks
Form 8K Protara Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Protara (TARA) Financial Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading; Market Reaction: The Stock Records a Flat Reaction in the Current UpdateForward EPS Estimate - vinanet.vn
Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat
Protara Therapeutics (TARA) Climbs 0.76% to $3.97 as Consolidation Builds Ahead of Clinical CatalystsBox Spread - dars.gov.et
Protara Therapeutics (NASDAQ:TARA) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
HC Wainwright Issues Negative Forecast for TARA Earnings - MarketBeat
Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA) - TradingView
Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA - MarketBeat
Janus Henderson Group (TARA holder) reports 8.4% Protara Therapeutics stake via Managed Portfolios - Stock Titan
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Protara Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus
Protara Therapeutics (NASDAQ:TARA) Issues Earnings Results - MarketBeat
Protara Therapeutics (TARA) Advances Clinical Trials Amid Mixed Market Signals - GuruFocus
Protara Therapeutics, Inc. 2Q 2026: Net income $(21.7)M, EPS $(0.36) — 10-Q Summary - TradingView
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - The Manila Times
Protara Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Protara Therapeutics reports Q2 2026 net loss $21.7M, cash ~$162M to fund operations into 2028 - TradingView
Protara Therapeutics: Q2 Earnings Snapshot - AOL.com
Press Release: Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - Moomoo
Protara Therapeutics rated Buy with $9.96 fair value, advancing treatments for NMIBC and choline deficiency. - Pluang
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline - Seeking Alpha
Protara Therapeutics (TARA) Rises Modestly to $4.12 as Stock Consolidates Between Key LevelsDark Pool Sentiment - dars.gov.et
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Protara Therapeutics (TARA) Projected to Announce Quarterly Earnings on Monday - MarketBeat
Protara Therapeutics Inc (TARA) Balance Sheet - TradingKey
Protara Therapeutics Inc (TARA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TARA|Protara Therapeutics Inc|Price:3.975|Chg%:+0.055 - TradingKey
Protara Therapeutics Inc (TARA) Institutional Confidence - TradingKey
TARA|Protara Therapeutics Inc|Price:3.900|Chg%:-0.060 - TradingKey
TARA|Protara Therapeutics Inc|Price:4.030|Chg%:+0.010 - TradingKey
TradingKey - TradingKey
Walleye Capital LLC Boosts Position in Protara Therapeutics, Inc. $TARA - MarketBeat
What Makes Protara Therapeutics (TARA) a New Buy Stock - Yahoo Finance
Should I buy Protara Therapeutics (TARA) - Zacks Investment Research
Protara Therapeutics (TARA) Edges Higher, Approaches Key Resistance Amid Low VolumeLong Term Entry Picks - vinanet.vn
Protara Therapeutics Q1 2026 Earnings: Narrower Loss Amid Continued Clinical DevelopmentHigh Growth Earnings - dars.gov.et
What's Driving Protara's Recent Surge - Kavout | AI
Protara Therapeutics (TARA) Edges Higher by 2.86%, Testing Resistance Near $4.54Equal Weight ETF - dars.gov.et
Millennium Group and Israel Englander report 5.7% stake in Protara (TARA) - Stock Titan
Protara Therapeutics focuses on rare disease programs as development continues - Ad Hoc News
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer - GlobeNewswire
Enterprise value to EBITDA forward of Protara Therapeutics, Inc. – NASDAQ:TARA - TradingView
Protara Therapeutics, Inc. Actuals & Estimates (HAM:1KPA) - TradingView
Finanzdaten der Protara Therapeutics Inc-Aktie (TARA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):